Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...

AbbVie has secured its fourth FDA approval for Vraylar, adding adjunctive therapy of major depressive disorder (MDD) to a list that includes schizophrenia and manic and depressive episodes in ...

A personalized circadian Zeitgeber therapy as an adjunctive treatment for alcohol use disorder patients: results of a pilot ...

Table 1. Clinical and preclinical studies reporting the effect of the KD on SUD. KD may be effective as a potential adjunctive therapy for SUD treatment. Importantly, it may have targeted protective ...

Concomitant use of statins improved survival among people with cancer treated with immune checkpoint inhibitors, according to ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Alto Neuroscienc announced that the U.S. Patent and Trademark Office has granted U.S. Patent Number 12,226,375, with method claims pertaining ...

Measles, one of the world’s most contagious infectious diseases, can cause serious complications – such as blindness, ...

Mannitol therapy is often used to reduce intracranial pressure from brain swelling in other ... and helped recover the BBB integrity in these mice (Gordon et al., 2015). The efficacy of DON as an ...